251 Spam-Free Article(s) Found
Sort:
Date
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Monday’s Close
INCY Incyte Corporation $67.04 $14.25B N/A
Article Searches
Here Are Biotech’s Big Pipeline Disappointments in 2018 https://www.fool.com/investing/2018/12/18/here-are-biotechs-big-pipeline-disappointments-in.aspx?source=iedfolrf0000001 Dec 18, 2018 - A number of companies suffered setbacks this year.
Incyte (INCY) Collaborates with Innovent for 3 Candidates http://www.zacks.com/stock/news/343302/incyte-incy-collaborates-with-innovent-for-3-candidates?cid=CS-ZC-FT-343302 Dec 17, 2018 - Incyte (INCY) collaborates with Innovent for the development of three clinical-stage product candidates: pemigatinib, itacitinib and parsaclisib.
Roche to Create Companion Diagnostic Test for Merck's Keytruda http://www.zacks.com/stock/news/342512/roche-to-create-companion-diagnostic-test-for-mercks-keytruda?cid=CS-ZC-FT-342512 Dec 12, 2018 - Roche (RHHBY) signs collaboration agreement with Merck for developing a companion diagnostic test to identify patients for treatment with the latter's Keytruda.
5 Top Drug/Biotech Merger & Acquisition Targets for 2019 http://www.zacks.com/stock/news/342034/5-top-drug-biotech-merger-acquisition-targets-for-2019?cid=CS-ZC-FT-342034 Dec 10, 2018 - Here are five stocks that are attractive and most likely to be takeout targets in 2019.
Incyte (INCY) Announces Positive Data on Jakafi for GVHD http://www.zacks.com/stock/news/341138/incyte-incy-announces-positive-data-on-jakafi-for-gvhd?cid=CS-ZC-FT-341138 Dec 04, 2018 - Incyte (INCY) announces positive data on lead drug Jakafi at the ASH meet for the indication of acute GVHD.
AstraZeneca's Imfinzi Fails in Lung Cancer Study, Stock Down http://www.zacks.com/stock/news/338332/astrazenecas-imfinzi-fails-in-lung-cancer-study-stock-down?cid=CS-ZC-FT-338332 Nov 19, 2018 - AstraZeneca (AZN) announced that Imfinzi as a monotherapy or in combination with tremelimumab failed to improve overall survival in first-line NSCLC. The combination had also failed to improve progression free survival last year.
Merck's (MRK) Keytruda Gets FDA Approval for Liver Cancer http://www.zacks.com/stock/news/336981/mercks-mrk-keytruda-gets-fda-approval-for-liver-cancer?cid=CS-ZC-FT-336981 Nov 12, 2018 - Merck's (MRK) Keytruda gains FDA approval for hepatocellular carcinoma (HCC) in patients previously treated with sorafenib.
Incyte Corp (INCY) Q3 2018 Earnings Conference Call Transcript https://www.fool.com/earnings/call-transcripts/2018/10/30/incyte-corp-incy-q3-2018-earnings-conference-call.aspx?source=iedfolrf0000001 Oct 30, 2018 - INCY earnings call for the period ending September 30, 2018.
Incyte (INCY) Q3 2018 Results - Earnings Call Transcript https://seekingalpha.com/article/4215968-incyte-incy-q3-2018-results-earnings-call-transcript?source=feed_sector_healthcare Oct 30, 2018 -
Biotech Stock Roundup: BIIB Tops, MACK Plunges, REGN's Asthma Drug Gets FDA Nod http://www.zacks.com/stock/news/330810/biotech-stock-roundup-biib-tops-mack-plunges-regns-asthma-drug-gets-fda-nod?cid=CS-ZC-FT-330810 Oct 24, 2018 - Earnings releases and key data-read outs were the key developments in the biotech sector last week.

Pages: 1234567891011...26

<<<Page 6>